CHICO, Calif. — Olivia Owlett chose to do her primary care residency in this Northern California college town largely because it faces many of the same health care challenges she grew up with. Owlett is one of four residents in the inaugural class of a three-year family medicine residency program run by the local nonprofit…
By WOJCIECH WASILEWSKI Dear Reader, if you’re looking for something soft and easy, please buy a different book. This one isn’t here to comfort you — it’s here to shake your lazy world, to shock you, to drag you out of the same lethargy I was trapped in for years after being diagnosed. If you…
Our updated explainer provides an overview of comprehensive managed care, the most common way states deliver Medicaid services to enrollees.
Providers need a revenue cycle management platform that is more affordable and accurate, said Jeremy Dekinsky, CEO of Smarter Technologies, during MedCity News’ INVEST conference. New Mountain Capital formed Smarter Technologies this week by combining three separate platforms it had already acquired. The post How a New PE-Backed RCM Company Plans to Fix the ‘Transactional…
Matthew Thompson, M.D., of Telescope Health, explains his organization’s unique model
KFF Health News Midwest correspondent Cara Anthony sat down with WORLD executive producer Chris Hastings to discuss the origins of the “Silence in Sikeston” project, which explores the impact of a 1942 lynching and a 2020 police shooting on a rural Missouri community. The collaboration with Retro Report includes a documentary film, educational videos, digital…
This policy watch outlines the groups of lawfully present immigrants that will lose access to federally funded health coverage due to the 2025 tax and budget law, and the CBO’s estimates of the increases in the uninsured.
By MIKE MAGEE In case you’ve missed it, sleep is all the rage in neurosciences these days. They are fast at work rebranding it “the brain’s rinse cycle.” The brain, protectively encased in an unyielding bony casing, lacks the delicate lymphatic system that transports used body metabolites to breakdown and extraction sites in all other parts…
Phase 2 data for Cargo Therapeutics’ CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025. The post…
Novartis’s Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals’ Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. The post Novartis Nabs First FDA Nod in Rare…